Detalhe da pesquisa
1.
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Cancer
; 124(11): 2355-2364, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29645086
2.
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 463-71, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25707361
3.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Clin Breast Cancer
; 22(3): 269-278, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34824002
4.
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
Clin Breast Cancer
; 19(1): 1-9, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30245148
5.
Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
Clin Breast Cancer
; 18(5): e781-e787, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29678476
6.
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Cancer Med
; 4(5): 673-81, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25556916
7.
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
Clin Breast Cancer
; 15(4): 251-8, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25640059